𝔖 Bobbio Scriptorium
✦   LIBER   ✦

New developments in surgical therapy for Parkinson's disease


Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
157 KB
Volume
9
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


F r a n c e . Surgical methods are still of interest when levodopa therapy fails. High frequency stimulation has similar effects and is safer than destruction in several basal ganglia, such as Ventral Intermediate Thalamus (Vim), Subthalamic Nucleus (STN) and Globus Pallidus Internus (GPi) has triggered a new trend in surgical treatment of movement disorders. Stereotactic implantation of chronic stimulating electrodes has been performed in Vim for tremor (113 patients, 172 thalami) and in STN for severe bradykinesia (6 patients. 11 nuclei). The target is located according to ventriculography, MRI. extracellular recording and stimulation at 130 Hz. There was no mortality, one large hematoma occured during the penetration of the cortex and the electrode was not inserted, morbidity was limited to transient hemiparesia in 3 patients, side effects were always reversible at the cessation of stimulation or by lowering the intensity, bilateral stimulation (54% of patients) did not induce neuro-psychological deficits. Vim stimulation (VimS) totally suppresses tremor in 80% of parkinsonian rest tremor. in 50 % of postural tremor and in


πŸ“œ SIMILAR VOLUMES


Neuroprotective Therapy for Parkinson's
✍ I.Shoulson and the Parkinson Study Group πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 103 KB πŸ‘ 1 views

In the context of degenerative disorders of the basal ganglia, neuroprotective therapy refers to interventions that preserve the integrity and function of vulnerable neurons and thereby slow or halt clinical decline. Decoppering therapy for Wilson's disease is the only established neuroprotective th

Milacemide therapy for Parkinson's disea
✍ M. E. Giuffra; V. H. Sethy; T. L. Davis; M. M. Mouradian; Dr. T. N. Chase πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 303 KB

## Abstract The clinical effects of central glutamatergic stimulation by the glycine prodrug milacemide were studied in six patients with Parkinson's disease under double‐blind, placebo‐controlled conditions. When administered as monotherapy at a single oral dose of 1,200 mg, the drug increased ove

Gene therapy for Parkinson's disease
✍ Tomas Bjorklund; Jeffrey H. Kordower πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 133 KB

## Abstract The once fantastic theoretical concept that patients with Parkinson's disease (PD) would receive gene therapy in an attempt to alleviate their symptoms and potentially modify the course of their disease has become a reality. On the basis of positive preclinical data, four different gene

Mitochondrial therapies for Parkinson's
✍ Bobby Thomas; M. Flint Beal πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 73 KB πŸ‘ 1 views

## Abstract Parkinson's disease (PD) is marked by widespread neurodegeneration in the brain in addition to a selective yet prominent and progressive loss of nigrostriatal dopaminergic neurons. Of the multiple theories suggested in the pathogenesis of PD, mitochondrial dysfunction takes a center sta

Crossroads in GDNF therapy for Parkinson
✍ Todd B. Sherer; Brian K. Fiske; Clive N. Svendsen; Anthony E. Lang; J. William L πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 68 KB πŸ‘ 1 views

## Abstract The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial‐derived neurotrophic factor (GDNF), directly into